• Gregory A Eschenauer, Peggy L Carver, Shu-Wen Lin, Kenneth P Klinker, Yee-Chun Chen, Brian A Potoski, Ryan K Shields, Cornelius J Clancy, Minh-Hong Nguyen, and Simon W Lam.
• Department of Pharmacy, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. eschenauerg@upmc.edu
• J. Antimicrob. Chemother. 2013 Apr 1;68(4):922-6.

ObjectivesWe studied whether fluconazole or echinocandin treatment of Candida glabrata fungaemia results in superior outcomes.MethodsA multicentre, retrospective study was performed with 224 adult patients who received ≥ 5 days of therapy with either fluconazole or an echinocandin as their first antifungal treatment after collection of a blood culture that grew C. glabrata. The primary outcome was day 14 complete response.ResultsPatients in the echinocandin group were generally more ill, both at baseline and at the time of the index culture. Day 14 complete response was obtained in 58/127 (46%) and 50/97 (52%) of the fluconazole and echinocandin patients, respectively (P=0.383). Logistic regression found intensive care unit admission to be associated with failure [OR 0.456 (0.217-0.957), P=0.038] and echinocandin therapy to be associated with day 14 complete response [OR 2.305 (1.124-4.727), P=0.023]. Twenty-eight day survival was similar between the fluconazole and echinocandin groups and logistic regression did not reveal antifungal therapy choice to be independently predictive of mortality. For patients treated with fluconazole, a dose:MIC ratio >12.5 (when compared with a ratio ≤ 12.5) was associated with a significantly higher day 14 complete response [4/20 (20%) ≤ 12.5 versus 50/102 (49%) >12.5, P=0.025].ConclusionsSeverity of illness and choice of antifungal predict response in patients with C. glabrata fungaemia. Antifungal choice, however, does not influence mortality. In addition, new CLSI C. glabrata fluconazole susceptibility breakpoints are predictive of response when fluconazole is dosed appropriately.

23 keywords...

hide…